STAAR Surgical Celebrates One Million Lens Milestone for Implantable Collamer® Lens (ICL)
April 10 2019 - 7:00AM
Business Wire
Visual Freedom from Glasses and Contact
Lenses Possible with the ICL
Safety and Effectiveness Supported by 100+
Peer-Reviewed Publications and 99.4% Patient
Satisfaction1
Lens Based Solution Addresses Explosive
Growth of Myopia Globally
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer, and marketer of implantable lenses and companion
delivery systems for the eye, today announced that more than one
million Visian implantable Collamer lenses (ICLs) have been
implanted globally. Currently approved versions of the ICL
available in more than 75 countries around the world address the
explosive growth of myopia, the need for distance vision
correction, that is predicted to impact 50% of the world’s
population by the year 2050.2 A one minute video celebrating the
one million ICL milestone is now available on various apps,
websites and at the following link:
https://vimeo.com/visianicl/1mmannouncement
“We celebrate the Visian ICL one million lens milestone with our
ophthalmology partners, clinicians, and patients who are elevating
the ICL to the premium and primary solution for refractive based
vision correction,” said Caren Mason, President and CEO of STAAR
Surgical Company. “More ICLs have been implanted since 2015 than
the prior 15 years of the ICL combined. Today’s milestone
represents only the beginning of our journey in raising ICL
awareness and adoption to delight surgeons and their patients. The
ICL, a remarkable biocompatible lens that works in harmony with a
person’s natural eye, is designed to improve vision following a
quick 20-30 minute procedure that many patients have described as
‘life changing.’ Through our ICL family of lenses STAAR aims to
significantly increase our share of the existing four million
annual refractive procedures globally, facilitate the market’s
return to peak procedure volumes, and further grow the overall
market with new and innovative lenses that address customer demands
such as a refractive solution for presbyopia that may eliminate the
need for reading glasses. Our work towards future milestones will
be bolstered by strong clinical evidence, surgeon training, and
ongoing operating and financial discipline.”
The Visian ICL family of lenses are phakic (natural crystalline
lens is not removed) intraocular lenses designed to correct for a
wide range of vision correction needs including myopia, hyperopia,
and astigmatism. The lenses are quiet in the eye. STAAR introduced
the first implantable Collamer lens (ICL) for myopia in 1997. U.S.
sales commenced in 2006 followed by the introduction of the ICL
with CentraFLOW technology outside the U.S. in September 2011 which
is now marketed as the EVO Visian ICL. EVO lenses have a port in
the center of the ICL optic intended to eliminate the need for a
peripheral iridotomy procedure days before the ICL implant. In
2016, STAAR launched Evolution in Visual Freedom websites in major
markets, rolled out new marketing material for surgeons and
patients, introduced the EVO+ for larger pupil sizes, and began
entering into strategic cooperation agreements with leading
ophthalmology clinics and surgeons that position the ICL as a
premium and primary refractive procedure for vision correction.
To learn more about the ICL please go to:
www.discovericl.com
1 99.4% of patients in a Patient Registry said they would have
the ICL procedure again. Patient Registry data on file.2
Ophthalmology 2016;123:1036-1042 © 2016 by the American Academy of
Ophthalmology; Myopia incidence was estimated at 1.4 Billion people
globally at time of study growing to 4.8 Billion people by 2050 or
predicted 50% of the estimated global population.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 30 years, designs, develops, manufactures, and markets
implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients,
lessening or eliminating the reliance on glasses or contact lenses.
All of these lenses are foldable, which permits the surgeon to
insert them through a small incision. STAAR’s lens used in
refractive surgery is called an Implantable Collamer® Lens or
“ICL,” which includes the EVO Visian ICL™ product line. More than
1,000,000 Visian ICLs have been implanted to date. To learn more
about the ICL go to: www.discovericl.com. STAAR markets lenses in
over 75 countries and had approximately 475 full-time equivalent
employees at December 28, 2018. Headquartered in Lake Forest, CA,
the company operates manufacturing facilities in Aliso Viejo, CA
and Monrovia, CA. For more information, please visit the Company’s
website at www.staar.com.
Safe Harbor
All statements in this press release that are not statements of
historical fact are forward-looking statements, including
statements about any of the following: any financial projections,
including those relating to the plans, strategies, and objectives
of management for 2019 or prospects for achieving such plans,
expectations for sales, revenue, or earnings, product safety or
effectiveness, and any statements of assumptions underlying any of
the foregoing. Important factors that could cause actual results to
differ materially from those indicated by such forward-looking
statements are set forth in the Company’s Annual Report on Form
10-K for the year ended December 28, 2018 under the caption “Risk
Factors,” which is on file with the Securities and Exchange
Commission and available in the “Investor Information” section of
the company’s website under the heading “SEC Filings.” We disclaim
any intention or obligation to update or revise any financial
projections or forward-looking statement due to new information or
events.
These statements are based on expectations and assumptions as of
the date of this press release and are subject to numerous risks
and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements.
The risks and uncertainties include the following: global economic
conditions; the discretion of regulatory agencies to approve or
reject existing, new or improved products, or to require additional
actions before approval, or to take enforcement action; potential
international trade disputes; and the willingness of surgeons and
patients to adopt a new or improved product and procedure. The
Visian ICL with CentraFLOW, now known as EVO Visian ICL, is not yet
approved for sale in the United States.
ATTENTION:
For Physicians: Please reference the Visian ICL Product
Information for a complete listing of indications, warnings, and
precautions.
For Patients: Before considering Visian ICL surgery you should
talk with your eye care professional about Visian ICL surgery,
especially the potential benefits, risks, and complications.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190410005309/en/
Investors & MediaEVC GroupBrian Moore,
310-579-6199bmoore@evcgroup.com
Doug Sherk, 415-652-9100
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Aug 2024 to Sep 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Sep 2023 to Sep 2024